Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRF617 Monotherapy and Combination in Advanced Solid Tumors
NCT04336098Phase 1Completed
- Sponsor
- Coherus BioSciences, Inc.
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of perenostobart in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC), gastric cancer (GC) and 2 more (8 arms), sponsored by Coherus BioSciences, Inc. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Mar 2020; status: completed.
02
Drugs
perenostobart
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)gastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04336098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336098.